Repurposed Cardiovascular Drugs as Adjuncts in Cancer Treatment

Why Repurposing Matters in Oncology

Drug repurposing is the strategic use of medicines already approved for one indication—often cardiovascular disease—to treat another, such as cancer. By matching known pharmacologic actions (e.g., inhibition of the mevalonate pathway by statins or β‑adrenergic blockade by propranolol) to oncogenic processes, researchers can accelerate therapeutic development, bypassing the years‑long safety and dosing studies required for novel agents. Leveraging cardiovascular drugs offers several concrete advantages: their safety profiles, dosing regimens, and pharmacokinetics are well‑characterized; they are inexpensive and widely available; and many possess pleiotropic anticancer mechanisms—including anti‑inflammatory, anti‑angiogenic, and immunomodulatory effects—that may enhance standard chemotherapy or immunotherapy. Hirschfeld Oncology embraces this paradigm by integrating repurposed cardiovascular agents as adjuncts to conventional regimens. The institute’s mission is to blend proven oncologic therapies with innovative, cost‑effective drugs—such as statins, β‑blockers, ACE inhibitors, and low‑dose aspirin—to improve response rates, reduce treatment‑related toxicity, and ultimately lower recurrence risk. By conducting rigorously designed trials and fostering multidisciplinary collaboration, Hirschfeld Oncology seeks to translate the promise of cardiovascular drug repurposing into tangible survival benefits for cancer patients.

Pancreatic Cancer: Spotlight on Repurposed Cardiovascular Agents

Pancreatic ductal adenocarcinoma remains a lethal disease, with a five‑year survival of less than 13 % and limited therapeutic options beyond intensive chemotherapy and radiation. High tumor heterogeneity and early metastasis create an urgent unmet need for adjunct strategies that can sensitize tumors, curb resistance, and improve tolerability.

A growing body of trials is testing non‑oncology cardiovascular agents as co‑therapies. Metformin, a biguanide with AMPK‑activating properties, is being evaluated in phase III studies for its capacity to impair tumor metabolism and augment gemcitabine‑based regimens. Statins such as simvastatin inhibit the mevalonate pathway and have entered early‑phase trials to determine whether they can reduce proliferation and improve progression‑free survival. Beta‑blockers, especially propranolol, are under investigation for their ability to block catecholamine‑driven angiogenesis and immune suppression; retrospective analyses suggest modest survival gains in pancreatic cohorts. Angiotensin‑II receptor blockers (ARBs) like losartan have shown promise in normalizing the tumor stromal matrix, thereby enhancing drug delivery. A phase II study combining losartan with FOLFIRINOX and radiation achieved unprecedented resection rates in locally advanced disease, supporting a “vascular‑normalization” approach.

Digitoxin, a cardiac glycoside, is currently being dosed in a Swedish trial to define safety and biomarker‑guided response in pancreatic cancer patients. Likewise, perhexiline maleate, a calcium‑channel blocker withdrawn for toxicity concerns, has demonstrated in organoid and mouse models the ability to suppress KRAS‑driven cholesterol synthesis and impede tumor growth, prompting pre‑clinical development of less‑toxic analogues.

Future research is shifting toward cancer prevention and treatment of high‑risk populations. Large cohort studies are evaluating whether chronic exposure to low‑dose aspirin, statins, or beta‑blockers can lower pancreatic cancer incidence or delay progression in individuals with familial or genetic susceptibility. such preventive trials could provide a cost‑effective, readily available adjunct to existing surveillance programs.

What repurposed drugs are currently being investigated for pancreatic cancer treatment? Several cardiovascular agents are in active evaluation: metformin, statins, beta‑blockers (particularly propranolol), ARBs (e.g., losartan), and the cardiac glycoside digitoxin. Pre‑clinical work also highlights perhexiline maleate as a promising candidate, while ongoing clinical protocols combine these drugs with standard chemotherapy and radiotherapy to improve outcomes.

Broad Oncology: Examples of Cardiovascular Drug Repurposing

Cardiovascular drug repurposing in oncology is gaining momentum as a cost‑effective strategy to enhance standard cancer therapy.

Metformin – Although an anti‑diabetic agent, metformin activates AMPK, inhibits mTOR, and lowers insulin‑like growth signaling. Pre‑clinical studies show reduced proliferation in breast, non‑small‑cell lung, and pancreatic cancer, and phase III trials are ongoing for five tumor types, reflecting its broad anti‑cancer potential.

Low‑dose aspirin – Irreversibly blocks platelet COX‑1, reducing platelet‑cancer cell aggregates that facilitate metastasis. Epidemiologic data link regular aspirin use to lower incidence and mortality in colorectal, prostate, and breast cancers, and adjuvant trials (e.g., CAPP2) have demonstrated a 13–17 % mortality reduction in colorectal cancer.

Statins – By inhibiting HMG‑CoA reductase, statins disrupt the mevalonate pathway, decreasing prenylation of Ras, Rho, and other oncogenic G‑proteins. Clinical evidence shows modest improvements in overall survival for prostate and breast cancers, and ongoing trials evaluate simvastatin with chemotherapy in gastric, colorectal, and bladder tumors.

Beta‑blockers – Non‑selective agents such as propranolol block β‑adrenergic signaling that drives catecholamine‑induced angiogenesis, invasion, and immune suppression. Retrospective analyses report a 15 % reduction in breast‑cancer recurrence and improved survival in pancreatic and colorectal cohorts.

Other agents – Thalidomide, once notorious for teratogenicity, is now an FDA‑approved treatment for multiple myeloma and is being explored in solid‑tumor protocols. Itraconazole, an antifungal, has shown activity against non‑small‑cell lung cancer by inhibiting angiogenesis and hedgehog signaling.

Together, these examples illustrate how repurposed cardiovascular drugs can act as adjuncts, targeting metabolism, inflammation, and tumor‑microenvironment pathways to improve cancer outcomes.

Adjuvant Therapy in Solid Tumors

Adjuvant therapy aims to eradicate microscopic disease after definitive surgery, thereby lowering recurrence risk. Standard systemic regimens include capecitabine after colorectal resection, anthracycline‑taxane combinations for early‑stage breast cancer, and fluoropyrimidine‑based chemoradiation for pancreatic ductal adenocarcinoma. Radiation is routinely added after breast‑conserving surgery or limb‑sparing resection of soft‑tissue sarcoma. Hormone‑blocking agents—tamoxifen, aromatase inhibitors, or luteinizing‑hormone‑releasing hormone agonists—are standard for hormone‑receptor‑positive breast and prostate cancers, while targeted biologics such as trastuzumab (HER2‑positive breast cancer) and osimertinib (EGFR‑mutated NSCLC) have entered the adjuvant setting. Immunotherapy (pembrolizumab, nivolumab) now complements surgery for high‑risk melanoma, NSCLC, and renal cell carcinoma.

Cardiovascular drugs are being explored as adjuncts to these established modalities. β‑blockers (e.g., propranolol) have shown epidemiologic associations with reduced recurrence in breast, colorectal, and pancreatic cancers, and early‑phase trials suggest they may blunt stress‑driven angiogenesis and improve progression‑free survival. Statins, by inhibiting the mevalonate pathway, modestly lower cancer‑specific mortality in retrospective cohorts and are being tested in phase II trials alongside chemotherapy for breast and pancreatic tumors. Low‑dose aspirin reduces platelet‑mediated tumor cell protection, decreasing metastasis in colorectal cancer. While most data are observational or from small prospective studies, the safety profile and low cost of these cardiovascular agents make them attractive candidates for integration into adjuvant protocols, pending results from larger randomized trials.

Lung Cancer and Cardiovascular Repurposing

Repurposed cardiovascular and anti‑inflammatory drugs have emerged as a rich source of adjuncts for non‑small‑cell lung cancer (NSCLC). The antidiabetic metformin, cholesterol‑lowering statins (e.g., atorvastatin, simvastatin) and the antifungal itraconazole have all shown modest activity in pre‑clinical models and retrospective cohorts, with metformin and statins improving progression‑free survival when added to standard chemotherapy. Valproic acid, originally an antiepileptic, exerts histone‑deacetylase inhibition that can sensitize NSCLC cells to EGFR‑TKIs. More recent agents such as the selective nuclear‑export inhibitor selinexor have demonstrated tumor control in KRAS‑mutant NSCLC when combined with docetaxel, while the anthelmintic niclosamide and the α‑blocker doxazosin target PI3K/AKT/mTOR and STAT3 pathways, respectively. Combination strategies are focusing on pairing these repurposed drugs with platinum‑based chemotherapy, immune‑checkpoint inhibitors, or targeted agents to overcome resistance and improve overall survival. The clinical‑trial landscape is expanding: phase II studies are testing metformin + pembrolizumab, simvastatin + osimertinib, and itraconazole + carboplatin/paclitaxel, while early‑phase trials evaluate selinexor and niclosamide in refractory disease. Future directions include biomarker‑driven patient selection, dose‑optimization using pharmacokinetic modeling, and larger randomized trials to establish definitive benefit.

Breast Cancer and Cardiovascular Adjuncts

Breast cancer research has embraced drug‑repurposing as a rapid, cost‑effective way to improve outcomes. Several FDA‑approved agents are being investigated as adjuncts to hormonal and chemotherapy regimens. Metformin, a biguanide antidiabetic, and the thiazolidinedione pioglitazone disrupt cancer metabolism and have shown modest improvements in response to endocrine therapy in early‑phase trials. Low‑dose aspirin and other NSAIDs target cyclo‑oxygenase‑driven inflammation, while Statins inhibit the mevalonate pathway, reducing prenylation of oncogenic Ras/Rho proteins and enhancing chemotherapy‑induced apoptosis. Beta‑blockers, particularly propranolol, are studied for their ability to block catecholamine‑driven β‑adrenergic signaling that promotes angiogenesis, invasion, and metastasis; retrospective analyses of breast‑cancer cohorts report a 15 % reduction in recurrence among beta‑blocker users. Beyond cardiovascular drugs, antiparasitic agents (e.g., mebendazole), antidepressants (e.g., sertraline), and antipsychotics (e.g., thioridazine) are under investigation for cancer‑stem‑cell targeting and DNA‑repair inhibition. Across these classes, the primary clinical endpoints are reductions in disease recurrence, metastasis, and improvements in overall survival. While pre‑clinical data are compelling, large randomized trials are still needed to confirm that these repurposed drugs can reliably augment standard breast‑cancer therapy.

Cardio‑Oncology Essentials: Monitoring, Toxicity, and Guidelines

Which chemotherapy agents are known to be cardiotoxic? Anthracyclines (doxorubicin, epirubicin, idarubicin, daunorubicin) cause dose‑dependent irreversible myocardial injury. HER2‑targeted antibodies (trastuzumab, pertuzumab) produce reversible left‑ventricular dysfunction. Anti‑VEGF agents (bevacizumab) and tyrosine‑kinase inhibitors (sunitinib, sorafenib) provoke hypertension and heart‑failure. High‑dose cyclophosphamide/ifosfamide, continuous 5‑fluorouracil or capecitabine, arsenic trioxide, bleomycin, busulfan, and taxanes (docetaxel, paclitaxel) also have cardiotoxic potential.

Current guidelines for cardiac monitoring during cancer therapy – Obtain a baseline transthoracic echocardiogram with LVEF (and GLS when available) before any high‑risk regimen. Repeat imaging every 3‑6 months for anthracycline or trastuzumab‑based treatment, then every 6 months for 2 years post‑therapy; low‑risk regimens may be im annually. Serial high‑sensitive troponin and BNP/NT‑proBNP at baseline and periodically help detect subclinical injury. Cardio‑protective strategies (cumulative anthracycline < 300 mg/m², dexrazoxane, early cardiology referral) are emphasized.

Common clinical signs of heart damage – Dyspnea on exertion or at rest, fatigue, peripheral edema, chest discomfort, palpitations, dizziness, and arrhythmias. Laboratory markers may rise; imaging shows reduced LVEF.

New FDA approval (2026) for Hodgkin lymphoma – Nivolumab (Opdivo) combined with AVD (doxorubicin, vinblastine, dacarbazine) for untreated stage III–IV classic Hodgkin lymphoma, highlighting the need for cardio‑oncology vigilance when pairing checkpoint inhibition with anthracyclines.

Adjuvant therapy vs. neoadjuvant therapy – Adjuvant treatment follows definitive surgery to eradicate microscopic disease; neoadjuvant therapy precedes surgery to shrink tumors, improve resectability, and provide early response data. In pancreatic cancer, Hirschfeld Oncology often uses neoadjuvant regimens before a Whipple, then adjuvant therapy to consolidate cure.

Side‑effect profile of adjuvant chemotherapy – Fatigue, nausea/vomiting, alopecia, myelosuppression (infection, anemia, bleeding), peripheral neuropathy, mucositis, and organ‑specific toxicities such as cardiotoxicity or pulmonary injury. Supportive care and monitoring are essential.

Looking Ahead: Integrating Cardiovascular Repurposing into Cancer Care

A growing pipeline of cardio‑oncology trials is testing cardiovascular agents as adjuncts to standard oncology regimens. Ongoing phase II/III studies are evaluating beta‑blockers (e.g., propranolol, carvedilol) with chemotherapy or immune checkpoint inhibitors in breast, lung and pancreatic cancers, while ARBs such as losartan are being combined with intensive FOLFIRINOX and radiation in locally‑advanced pancreatic adenocarcinoma (Massachusetts General Hospital trial). Statins and low‑dose aspirin are also in late‑stage trials for colorectal and breast cancer, probing both survival benefit and toxicity mitigation.

Beyond treatment, several investigators are shifting focus to primary prevention. Observational data suggest that chronic statin or aspirin use lowers cancer incidence in high‑risk cohorts; prospective prevention trials (e.g., CAPP2 for aspirin, ongoing statin prevention studies) aim to confirm these signals and define optimal dosing.

Hirschfeld Oncology is poised to translate these findings into clinical practice. Its multidisciplinary model—oncologists, cardiologists, pharmacologists, and data scientists—prioritizes rigorous evidence, ongoing trial enrollment, and biomarker‑driven patient selection. By integrating repurposed cardiovascular drugs into personalized adjuvant and preventive strategies, Hirschfeld Oncology seeks to improve long‑term outcomes while preserving cardiac health.